MedTrace Logo

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

NCT06212297 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-06-29

No results posted yet for this study

Summary

Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.

Conditions

  • Inherited Retinal Dystrophy

Interventions

GENETIC

LX101

Subretinal administration of LX101 to the contralateral, previously uninjected eye

Sponsors & Collaborators

  • Innostellar Biotherapeutics Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-12
Primary Completion
2025-02-06
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06212297 on ClinicalTrials.gov